INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)
- Status
- WITHDRAWN
- Phase
- PHASE3
Clinical Trials Related to Retifanlimab
Related studies linked through entity extraction aliases.
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)
- Status
- COMPLETED
- Phase
- PHASE2
INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
- Status
- COMPLETED
- Phase
- PHASE2
MGD009/MGA012 Combination in Relapsed/Refractory Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Combination Study of SV-BR-1-GM With Retifanlimab
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2